作者
Carsten T Charlesworth, Priyanka S Deshpande, Daniel P Dever, Joab Camarena, Viktor T Lemgart, M Kyle Cromer, Christopher A Vakulskas, Michael A Collingwood, Liyang Zhang, Nicole M Bode, Mark A Behlke, Beruh Dejene, Brandon Cieniewicz, Rosa Romano, Benjamin J Lesch, Natalia Gomez-Ospina, Sruthi Mantri, Mara Pavel-Dinu, Kenneth I Weinberg, Matthew H Porteus
发表日期
2019/2
期刊
Nature medicine
卷号
25
期号
2
页码范围
249-254
出版商
Nature Publishing Group US
简介
The CRISPR–Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR–Cas9 system to therapeutically correct human genetic diseases, , , , –. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes,. Given that these two bacterial species infect the human population at high frequencies,, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells …
引用总数
201820192020202120222023202455129148214157141102
学术搜索中的文章